Sana Biotechnology enters the second half of 2026 with a tightening contradiction: short sellers are quietly adding exposure while options traders have turned more bullish than at almost any point in the past year.
The short-side rebuilding is the more concrete story. Short interest has climbed to 15.9% of the free float — up roughly 10% over the past month and accelerating in the final week of June, with an additional 1.2 million shares added between June 26 and June 30. The official FINRA settlement data corroborates the trend, placing short shares at 40.7 million as of mid-June, a figure the ORTEX daily estimate has since pushed well beyond. Days to cover sits at over 11, meaning at current trading volumes shorts would need nearly two and a half weeks to exit — not an extreme, but a meaningful overhang for a $3.49 stock. ORTEX's short score has hit 80.2 on June 30, its highest reading in at least two weeks, reinforcing the directional drift. What keeps this from being a pure bear story is the borrow market: cost to borrow remains almost trivially cheap at 0.54%, and availability — currently at 77.8% — has actually tightened sharply this week, down from above 147% as recently as June 26. That rapid compression in available shares is worth watching; it suggests new demand for borrows is absorbing the pool faster than it is being replenished.
Options positioning tells a starkly different story. Call demand has overwhelmed puts to an extreme degree, with the put/call ratio dropping to 0.15 — more than 3.5 standard deviations below its 20-day average of 0.17. That z-score is the lowest in the past year, sitting well below the 52-week low of 0.11 and well under the recent average. In plain terms, options traders are expressing one of the most one-sided bullish tilts on record for this name. Whether that reflects genuine conviction in upcoming catalysts or simply a lack of demand for downside protection is unclear, but the divergence from what short sellers are doing is hard to ignore.
The Street broadly agrees with the bull side, at least on direction. All six analysts with current coverage carry buy-equivalent ratings — Outperform or Buy across Wedbush, HC Wainwright, BofA Securities, and Citizens — with targets clustered in the $7–$8 range against a $3.49 current price. The most recent move came from Wedbush in April, which lifted its target to $7 from $6 while maintaining Outperform. HC Wainwright trimmed to $7 from $9 in March, reflecting some recalibration on clinical timelines rather than a directional shift. The implied upside from the consensus target is roughly 100%, an unusually wide gap even by biotech standards. The bull thesis centres on growing biologics adoption and SG299's potential in lupus nephritis. Bears point to the same program — questioning whether the efficacy and safety data will hold and noting the severe nature of the indication. With EPS forward estimates improving strongly year-over-year (ranking in the 91st percentile on that factor) but momentum scores soft and the Piotroski F-score at zero, valuation multiples are largely irrelevant here; this is a binary clinical story.
The earnings record does not flatter patience. All four recent prints produced negative next-day reactions, ranging from -1.6% to -14.1%, with the most recent June 4 result hitting hardest at -14%. Five-day reactions were similarly negative across the board. The next event is scheduled for August 10, giving the market roughly six weeks to form a view. The interesting asymmetry going into that print is that short sellers appear to be building positions into what options traders expect to be a catalyst. The key variable between now and August is whether any interim clinical data or pipeline updates on SG299 change that equation — and whether availability continues to tighten as those two camps pull in opposite directions.
See the live data behind this article on ORTEX.
Open SANA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
